Progestin on its own carries little to no blood clot risk for most people, which makes it fundamentally different from combined hormonal contraceptives that pair estrogen with a progestin. Estrogen is the primary driver of clotting risk in hormonal birth control and hormone therapy. But the answer isn’t a simple “no” across the board. The type of progestin, how it’s delivered, and your individual risk factors all matter.
Why Estrogen Gets the Blame, Not Progestin
Blood clots associated with hormonal birth control are overwhelmingly linked to estrogen. Estrogen increases the liver’s production of clotting factors, tipping the balance toward clot formation. Combined pills, patches, and vaginal rings all contain estrogen, which is why they carry a measurable increase in venous thromboembolism (VTE), the medical term for blood clots in veins, typically in the legs or lungs.
Progestin-only methods skip estrogen entirely, and the evidence consistently shows they don’t raise clot risk the same way. An updated systematic review in the journal Contraception found that VTE and arterial clot risks were “generally not elevated” with progestin-only pills, hormonal IUDs, or implants. For hormonal IUDs specifically, none of the studies found a statistically significant increase in clots compared to non-use, with risk estimates ranging from 0.3 to 1.0 (where 1.0 means no difference from baseline). A separate analysis from the American Society of Hematology confirmed that the levonorgestrel IUD carries no additional VTE risk, with a relative risk of 0.6.
The Exception: Injectable Progestin
One progestin-only method does appear to raise clot risk: the injection (commonly known as Depo-Provera), which uses a synthetic progestin called medroxyprogesterone acetate, or DMPA. Unlike the low, steady doses delivered by IUDs or implants, the injection delivers a large dose that enters the bloodstream all at once and maintains higher systemic levels for months.
The Leiden Thrombophilia Study tracked women who had already experienced a first clot and found that those using progestin-only methods had a recurrence rate of about 38 per 1,000 women-years, compared to 10.5 per 1,000 in non-users. The researchers noted that recurrences occurred specifically in women using DMPA, not in those using oral progestins, IUDs, or implants. The CDC’s medical eligibility guidelines reflect this distinction: for women at higher risk of recurrent clots, injectable DMPA gets a category 3 rating (risks generally outweigh benefits), while implants and progestin-only pills get a category 2 (benefits generally outweigh risks).
The Type of Progestin Matters
Not all progestins are chemically identical, and their effects on clotting vary. This is most visible in combined pills, where the progestin component can shift the overall risk. The FDA concluded that pills containing drospirenone (found in brands like Yaz and Yasmin) may carry a higher clot risk than pills with older progestins like levonorgestrel. Some studies reported as high as a threefold increase in clots with drospirenone-containing pills compared to levonorgestrel-containing pills, while others found no additional risk. An FDA-funded study estimated the increase at roughly 1.5-fold.
It’s worth noting that this comparison involves combined pills, so estrogen is still in the mix. The progestin type appears to modify the risk rather than create it from scratch. Still, if you’re choosing between combined options, the generation of progestin is a factor your provider may consider.
Progestin in Menopause Hormone Therapy
For people using hormone therapy after menopause, the type of progestin paired with estrogen makes a significant difference. The ESTHER study, published in Circulation, compared different progestins used alongside oral estrogen and found strikingly different results. Micronized progesterone (a form identical to the body’s own hormone) showed no increased clot risk, with an odds ratio of 0.7. Pregnane-derived progestins were similarly neutral at 0.9. But norpregnane derivatives, a class of synthetic progestins, were associated with a nearly fourfold increase in VTE risk (odds ratio of 3.9).
The researchers concluded that micronized progesterone and pregnane derivatives “may be safe with respect to thrombotic risk,” while norpregnane derivatives are “thrombogenic.” If you’re on or considering menopausal hormone therapy, this distinction between natural and synthetic progestins is one of the most clinically meaningful choices in the prescription.
How Body Weight Changes the Picture
Obesity independently raises clot risk by about 2.5 times compared to people with a BMI under 30. When researchers looked at how body weight interacts with progestin-only contraception using a large administrative database, they found that obese users of most progestin-only options had significantly higher VTE rates than non-obese users. The highest rates appeared among obese users of oral norethindrone at higher doses and all forms of injectable medroxyprogesterone acetate.
Interestingly, this interaction wasn’t seen with every progestin formulation. Drospirenone-only pills and high-dose norethindrone didn’t show the same statistically significant increase in obese users. The takeaway isn’t that progestin-only methods are dangerous at higher body weights, but that individual risk factors compound. If you have a higher BMI and are choosing a progestin-only method, the delivery method and specific formulation are worth discussing.
If You Have a History of Blood Clots
The CDC’s 2024 U.S. Medical Eligibility Criteria provide clear guidance for people with a clotting history. Progestin-only pills, implants, and hormonal IUDs all receive a category 2 rating for most people with current or past clots, meaning the benefits of using them generally outweigh the risks. Having a family history of clots in a first-degree relative gets a category 1, meaning no restriction at all.
The one area of caution is injectable DMPA for people at higher risk of recurrent clots, such as those with inherited clotting disorders like factor V Leiden, active cancer, or a history of multiple clot episodes. In those cases, DMPA gets a category 3. Even then, progestin-only methods as a class remain far more accessible than combined hormonal options, which receive a category 4 (unacceptable risk) for anyone with a clotting history.
The CDC also notes a practical benefit: progestin-only contraceptives can help manage heavy bleeding and hemorrhagic ovarian cysts in people taking blood thinners, which means they sometimes serve a dual purpose for those already being treated for clots.
Comparing Progestin-Only Methods at a Glance
- Hormonal IUDs (Mirena, Kyleena, others): Release tiny amounts of levonorgestrel locally into the uterus. No measurable increase in clot risk. Considered safe even for people with clotting histories.
- Progestin-only pills (the “mini-pill”): Low systemic progestin dose. No statistically significant increase in VTE risk in the general population or in people with clotting risk factors.
- Subdermal implants (Nexplanon): Release etonogestrel steadily over years. Available data show no additional VTE risk, though fewer large studies exist compared to IUDs.
- Injectable DMPA (Depo-Provera): Higher systemic dose delivered every three months. Appears to increase VTE risk, particularly in people who already have clotting risk factors or higher body weight.
The pattern is consistent: the lower the systemic progestin exposure and the more localized the delivery, the lower the clotting concern. Hormonal IUDs sit at the safest end of this spectrum because most of the hormone stays in the uterus rather than circulating through the bloodstream. Injectable DMPA sits at the other end, delivering a bolus dose that circulates systemically for months.